PMID- 26428280
OWN - NLM
STAT- MEDLINE
DCOM- 20160223
LR  - 20220408
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 46
IP  - 12
DP  - 2015 Dec
TI  - Significantly increased PELP1 protein expression in primary and metastatic 
      triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's 
      potential role in triple-negative breast carcinoma.
PG  - 1829-35
LID - S0046-8177(15)00286-5 [pii]
LID - 10.1016/j.humpath.2015.07.023 [doi]
AB  - PELP1 is a novel coregulator of nuclear hormone receptors and is implicated in 
      playing a role in driving breast cancer and enhancing metastatic potential. The 
      PELP1 protein expression and potential role of PELP1 in triple-negative breast 
      carcinoma (TNBC) have not been well characterized. We investigated PELP1 
      expression by immunohistochemistry in primary and metastatic triple-negative 
      tumors in human tissues and compared its expression with GATA-binding protein 3 
      (GATA3), a novel diagnostic marker for TNBC. We examined the expression of PELP1 
      and GATA3 in 70 primary TNBC cases and found that PELP1 had a significantly 
      higher frequency of expression compared to GATA3 (96% versus 46%; P < .0001). The 
      mean extent score of expression of PELP1 was also significantly higher than 
      GATA3's expression (3.87 +/- 0.07 versus 0.91 +/- 0.15; P < .0001). PELP1 had 
      stronger staining intensity than GATA3. Furthermore, PELP1 immunoreactivity was 
      consistently maintained in paired primary and metastatic TNBC cases (100%). The 
      frequency of PELP1 expression (100%) in metastatic triple-negative tumors was 
      higher than that of GATA3 (40%) in the same tumors (P < .0001). These findings 
      indicate that PELP1 is a much more sensitive marker than GATA3 for TNBCs. PELP1 
      may have diagnostic utility for metastatic TNBC in appropriate settings, such as 
      history of primary TNBC in cases where the primary is negative for GATA3, 
      mammaglobin, and GCDFP-15. The diffuse and strong nuclear immunoreactivity of 
      PELP1 in most cases suggests that PELP1 may be a molecular target for the 
      treatment of TNBC. We hope that this study will provide insights into the role of 
      PELP1 in TNBC.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Dang, Daniel N
AU  - Dang DN
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390-9073.
FAU - Raj, Ganesh
AU  - Raj G
AD  - Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390-9073.
FAU - Sarode, Venetia
AU  - Sarode V
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390-9073.
FAU - Molberg, Kyle H
AU  - Molberg KH
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390-9073.
FAU - Vadlamudi, Ratna K
AU  - Vadlamudi RK
AD  - Department of Obstetrics & Gynecology, University of Texas Health Science Center, 
      San Antonio, TX 78229.
FAU - Peng, Yan
AU  - Peng Y
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390-9073. 
      Electronic address: yan.peng@utsouthwestern.edu.
LA  - eng
PT  - Journal Article
DEP - 20150812
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Co-Repressor Proteins)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (GATA3 protein, human)
RN  - 0 (PELP1 protein, human)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Biomarkers, Tumor/*analysis
MH  - Co-Repressor Proteins/analysis/*biosynthesis
MH  - Female
MH  - GATA3 Transcription Factor/analysis/biosynthesis
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Neoplasm Metastasis/pathology
MH  - Tissue Array Analysis
MH  - Transcription Factors/analysis/*biosynthesis
MH  - Triple Negative Breast Neoplasms/*pathology
OTO - NOTNLM
OT  - GATA3
OT  - Immunohistochemistry
OT  - Metastasis
OT  - PELP1
OT  - Triple-negative breast carcinoma
EDAT- 2015/10/03 06:00
MHDA- 2016/02/26 06:00
CRDT- 2015/10/03 06:00
PHST- 2015/05/24 00:00 [received]
PHST- 2015/07/23 00:00 [revised]
PHST- 2015/07/29 00:00 [accepted]
PHST- 2015/10/03 06:00 [entrez]
PHST- 2015/10/03 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - S0046-8177(15)00286-5 [pii]
AID - 10.1016/j.humpath.2015.07.023 [doi]
PST - ppublish
SO  - Hum Pathol. 2015 Dec;46(12):1829-35. doi: 10.1016/j.humpath.2015.07.023. Epub 
      2015 Aug 12.